EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines

Daphnee S Pushparajah, Jan Geissler, Niels Westergaard

Abstract

The value of collaborations and partnerships between different stakeholders to achieve optimum outcomes in the medicines research and development process is being recognised. Historically, there has been a lack of collaboration with patients and many research consortiums consisting mainly of academia and/or industry partners. Although patient experts are able to bring valuable first-hand experience and insights, they might not possess detailed knowledge about medicines research and development to actively participate in the collaboration process. The European Patients’ Academy on Therapeutic Innovation (EUPATI) was established to deliver training to patient experts, and education resources
to patient advocates and members of the health-interested public across Europe. EUPATI was launched in February 2012 and is a patient-led Innovative Medicines Initiative (IMI) project, with a multi-stakeholder consortium of patient advocates, academia, industry and not-for-profit organisations. Training and educational materials will be used for capacity building among patients, for educating patient advocates and for informing the health-interested public. The successful uptake of EUPATI’s materials will hopefully translate into a new paradigm of increased patient involvement across the entire medicines research and development process, bringing mutual benefits, including better medicines, to all stakeholders.


Keywords

EUPATI; medicines research and development; IMI; patients involved; multi-stakeholder collaborations; informed patient; patients engaged

Full Text:

PDF

References

Kain D, 2011, Pfizer/UC San Diego Health Sciences Drug Discovery partnership aims to speed delivery of promising therapies to patients, University of California, San Diego News, viewed May 18, 2015,

University of Cambridge launches Open Innovation drug discovery initiative with GSK n.d., viewed May 18, 2015,

Fenton L, Rigney M, LICSW, et al. 2009, Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists. Community Oncology, vol.6(5): 207–228.

Hibbard J H, 2003, Engaging health care consumers to improve the quality of care. Medical Care, vol.41(1): 161–170.

Hoos A, Anderson J, Boutin M, et al. 2015, Partnering with patients in the development and lifecycle of medi-cines: a call for action. Therapeutic Innovation & Regu-latory Science. http://dx.doi.org/10.1177/2168479015580384.

The Impatient Patient: From Anger to Activism, Euro-pean Aids Treatment Group, n.d., viewed May 18, 2015,

Financing research n.d., viewed May 18, 2015,

Patientpartner n.d., viewed May 18, 2015,

Patients Academy n.d., viewed May 18, 2015,

IMI Projects n.d., viewed May 18, 2015,

Chakradhar S, 2015, Training on trials: Patients taught the language of drug development. Nature Medicine, vol.21: 209–210. http://dx.doi.org/10.1038/nm0315-209.

Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion n.d., viewed May 18, 2015,

Hay M, Thomas D W, Craighead J L, et al. 2014, Clini-cal development success rates for investigational drugs. Nature Biotechnology, vol.32: 40–51. http://dx.doi.org/10.1038/nbt.2786.

Parsons S, Starling I, Mullan-Jensen C, et al. 2015, What the public knows and wants to know about medi-cines research and development - A survey of the gener-al public in six European countries. BMJ Open, vol.5: e006420. http://dx.doi.org/10.1136/bmjopen-2014-006420.

Patients Academy: Events n.d., viewed May 18, 2015,

Eupati 2015 Workshop n.d., viewed May 18, 2015,

Patient involvement in medicines development: moving from theory to reality n.d., viewed May 18, 2015,


DOI: http://dx.doi.org/10.18063/JMDS.2015.01.011
(156 Abstract Views, 75 PDF Downloads)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Daphnee S. Pushparajah, Jan Geissler, Niels Westergaard

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.